GC:
"We believe there is potential for investor upside in the short to medium term "
"Our advisors are now carefully examining various potential opportunities."
"We have made excellent progress along the formulation and manufacturing path (of zafirlukast)"
"Drug development and commercialisation is a laborious and complicated process, but we are encouraged by strong clinical results and remain confident in the science underpinning our lead programs."
"From this basis, we look forward to delivering shareholder returns as we achieve next milestones or strike a partnership arrangement."
Add to My Watchlist
What is My Watchlist?
